文献速递乳腺癌

POETIC研究:围手术期内分泌治疗后的长期结局与Ki67预后价值

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2020-01-01

POETIC是一项开放标签、多中心、平行组、随机3期试验,纳入4480例绝经后激素受体阳性可手术乳腺癌患者,按2:1随机分为围手术期芳香化酶抑制剂(POAI)组或对照(无POAI)组。

要点

  • POAI未改善无复发生存,但可安全用于基于Ki67的辅助治疗选择。

核心结论

  • 围手术期芳香化酶抑制剂未显示改善治疗结局,但可无损害地用于基于肿瘤Ki67选择辅助治疗。
  • 基线Ki67低或POAI诱导的2周Ki67低者,标准辅助内分泌治疗结局较好。
  • POAI诱导的2周Ki67仍高者可能从进一步辅助治疗或新疗法试验中获益。

研究设计与样本

  • 开放标签、多中心、平行组、随机3期试验,在英国130家医院开展。
  • 纳入4480例≥50岁、WHO体能状态0-1、激素受体阳性可手术乳腺癌的绝经后女性。
  • 主要终点为复发时间;Ki67以10%为界二分,分析其与疾病结局的关联。
  • 临床终点主要分析采用改良意向治疗(排除撤回知情同意者);Ki67分析纳入有配对Ki67值的全部随机患者。

主要发现

  • 最常见3级不良事件为潮热(POAI组2801例中20例[1%] vs 对照组1400例中6例[<1%])和肌肉骨骼疼痛(29例[1%] vs 13例[1%]);无治疗相关死亡。

关键数值与推荐

  • Ki67以10%为界进行二分。
  • 随机按2:1分配,采用计算机生成置换区组(区组大小6或9)中央随机,按医院分层。

临床怎么用

  • 围手术期短期芳香化酶抑制剂可安全使用,不改善结局但可用于基于Ki67的辅助治疗决策。
  • HER2阴性且基线及2周Ki67均低者,可考虑标准辅助内分泌治疗并结合临床病理因素。
  • POAI后2周Ki67仍高者复发风险较高,可考虑强化辅助治疗或参加新疗法临床试验。
  • HER2阳性者Ki67预后区分度有限,辅助治疗决策应结合HER2靶向治疗等综合因素。

局限性

  • 治疗分配未设盲。
  • Ki67分析仅纳入有配对Ki67值的可评估患者,可能存在选择偏倚。
  • 研究在英国开展,辅助治疗按英国当地标准实践,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes in women with operable oestrogen receptor-positive primary breast cancer. It has also been suggested that tumour Ki67 values after 2 weeks (Ki672W) of POAI predicts individual patient outcome better than baseline Ki67 (Ki67B). The POETIC trial aimed to test these two hypotheses. METHODS: POETIC was an open-label, multicentre, parallel-group, randomised, phase 3 trial (done in 130 UK hospitals) in which postmenopausal women aged at least 50 years with WHO performance status 0-1 and hormone receptor-positive, operable breast cancer were randomly assigned (2:1) to POAI (letrozole 2·5 mg per day orally or anastrozole 1 mg per day orally) for 14 days before and following surgery or no POAI (control). Adjuvant treatment was given as per UK standard local practice. Randomisation was done centrally by computer-generated permuted block method (variable block size of six or nine) and was stratified by hospital. Treatment allocation was not masked. The primary endpoint was time to recurrence. A key second objective explored association between Ki67 (dichotomised at 10%) and disease outcomes. The primary analysis for clinical endpoints was by modified intention to treat (excluding patients who withdrew consent). For Ki67 biomarker association and endpoint analysis, the evaluable population included all randomly assigned patients who had paired Ki67 values available. This study is registered with ClinicalTrials.gov, NCT02338310; the European Clinical Trials database, EudraCT2007-003877-21; and the ISRCTN registry, ISRCTN63882543. Recruitment is complete and long-term follow-up is ongoing. FINDINGS: Between Oct 13, 2008, and April 16, 2014, 4480 women were recruited and randomly assigned to POAI (n=2976) or control (n=1504). On Feb 6, 2018, median follow-up was 62·9 months (IQR 58·1-74·1). 434 (10%) of 4480 women had a breast cancer recurrence (280 [9%] POAI; 154 [10%] control), hazard ratio 0·92 (95% CI 0·75-1·12); p=0·40 with the proportion free from breast cancer recurrence at 5 years of 91·0% (95% CI 89·9-92·0) for patients in the POAI group and 90·4% (88·7-91·9) in the control group. Within the POAI-treated HER2-negative subpopulation, 5-year recurrence risk in women with low Ki67B and Ki672W (low-low) was 4·3% (95% CI 2·9-6·3), 8·4% (6·8-10·5) with high Ki67B and low Ki672W (high-low) and 21·5% (17·1-27·0) with high Ki67B and Ki672W (high-high). Within the POAI-treated HER2-positive subpopulation, 5-year recurrence risk in the low-low group was 10·1% (95% CI 3·2-31·3), 7·7% (3·4-17·5) in the high-low group, and 15·7% (10·1-24·4) in the high-high group. The most commonly reported grade 3 adverse events were hot flushes (20 [1%] of 2801 patients in the POAI group vs six [<1%] of 1400 in the control group) and musculoskeletal pain (29 [1%] vs 13 [1%]). No treatment-related deaths were reported. INTERPRETATION: POAI has not been shown to improve treatment outcome, but can be used without detriment to help select appropriate adjuvant therapy based on tumour Ki67. Most patients with low Ki67B or low POAI-induced Ki672W do well with adjuvant standard endocrine therapy (giving consideration to clinical-pathological factors), whereas those whose POAI-induced Ki672W remains high might benefit from further adjuvant treatment or trials of new therapies. FUNDING: Cancer Research UK.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Smith I, Robertson J, Kilburn L, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 2020. PMID: 33152284. doi:10.1016/S1470-2045(20)30458-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。